BrightSpring Health Services Specialty Pharmacy Onco360 Chosen as National Partner for XPOVIO, a First-in-Class Multiple Myeloma Treatment
LOUISVILLE, Ky. March 14, 2024 - BrightSpring Health Services (NASDAQ: BTSG) has recently announced that its subsidiary, Onco360, has become the national specialty pharmacy network partner for XPOVIO (selinexor), a groundbreaking XPO-1 inhibitor used for the treatment of patients with multiple myeloma. Onco360 is one of the largest independent oncology pharmacies in the United States and currently holds a portfolio of 116 limited distribution drugs in collaboration with various pharmaceutical and biotech companies.
Multiple myeloma is a type of blood cancer that affects plasma cells, which are a vital component of the immune system. Despite advancements in treatment options, patients with multiple myeloma often face significant challenges due to the complexities involved in managing the disease. BrightSpring’s selection of Onco360 as a preferred pharmacy demonstrates the company’s commitment to providing excellent patient care and offering innovative treatment solutions in the field of oncology.
XPOVIO, developed by Karyopharm Therapeutics, has gained attention for its ability to target and inhibit XPO-1, a protein responsible for the growth and survival of cancer cells in multiple myeloma. By blocking the function of XPO-1, XPOVIO disrupts the cancer cells’ ability to proliferate and spread, thereby increasing the chances of remission and improving overall patient outcomes.
The decision to partner with Onco360 as the national specialty pharmacy network for XPOVIO highlights the pharmacy’s expertise and reputation in the oncology field. Onco360’s comprehensive understanding of the unique challenges faced by patients with multiple myeloma, along with its extensive experience in managing limited distribution drugs, positions the pharmacy as an essential player in delivering XPOVIO to the patients who need it most.
BrightSpring’s dedication to patient care and commitment to improving treatment options for individuals with multiple myeloma are evident through their collaboration with Onco360. By joining forces with Karyopharm Therapeutics, BrightSpring aims to provide patients with access to this groundbreaking therapy, ensuring that the best possible care is delivered to individuals battling this challenging disease.
In conclusion, BrightSpring Health Services has selected Onco360 as the national specialty pharmacy network partner for XPOVIO, a first-in-class treatment for multiple myeloma. By offering access to this innovative therapy, BrightSpring empowers patients and healthcare providers to take significant strides in combating this form of blood cancer. This partnership underscores BrightSpring’s commitment to exceptional patient care and signifies Onco360’s reputable position as a pioneer in the field of oncology.
Comments